-
1
-
-
2642709177
-
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
-
HIV Outpatient Study Investigators
-
Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
-
(1998)
N Engl J Med
, vol.338
, pp. 853-860
-
-
Palella, F.J.1
Delaney, K.M.2
Moorman, A.C.3
-
2
-
-
84874514203
-
Decreasing mortality and patterns of causes of death in the Swiss HIV Cohort Study
-
Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013;14:195-207.
-
(2013)
HIV Med
, vol.14
, pp. 195-207
-
-
Weber, R.1
Ruppik, M.2
Rickenbach, M.3
-
3
-
-
84872232623
-
Cause specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome negative individuals followed simultaneously in long-term cohort studies, 1984-2008
-
Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013;177:116-125.
-
(2013)
Am J Epidemiol
, vol.177
, pp. 116-125
-
-
Wada, N.1
Jacobson, L.P.2
Cohen, M.3
French, A.4
Phair, J.5
Munoz, A.6
-
4
-
-
70350457524
-
Human immunodeficiency virus in an aging population; A complication of success
-
Kirk J, Goetz MB. Human immunodeficiency virus in an aging population; A complication of success. J Am Geriatr Soc 2009;57:2129-2138.
-
(2009)
J Am Geriatr Soc
, vol.57
, pp. 2129-2138
-
-
Kirk, J.1
Goetz, M.B.2
-
5
-
-
84866379288
-
Allcause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV coinfection
-
Hernando V, Perez-Cachafeiro S, Lewden C, et al. Allcause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV coinfection. J Hepatol 2012;57:743-751.
-
(2012)
J Hepatol
, vol.57
, pp. 743-751
-
-
Hernando, V.1
Perez-Cachafeiro, S.2
Lewden, C.3
-
6
-
-
84921030343
-
Burden of HIV and hepatitis C co-infection: The changing epidemiology of hepatitis C in HIV-infected patients in France
-
Cacoub, P, Dabis F, Costagliola, D, et al. Burden of HIV and hepatitis C co-infection: The changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int 2015;35:65-70.
-
(2015)
Liver Int
, vol.35
, pp. 65-70
-
-
Cacoub, P.1
Dabis, F.2
Costagliola, D.3
-
7
-
-
34548709023
-
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus infected patients undergoing highly active antiretroviral therapy
-
Pineda JA, García-García JA, Aguilar-Guisado M, et al; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus infected patients undergoing highly active antiretroviral therapy. Hepatology 2007;46:622-630.
-
(2007)
Hepatology
, vol.46
, pp. 622-630
-
-
Pineda, J.A.1
García-García, J.A.2
Aguilar-Guisado, M.3
-
8
-
-
17044412029
-
Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C
-
Buti M, San Miguel R, Brosa M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005;42:639-645.
-
(2005)
J Hepatol
, vol.42
, pp. 639-645
-
-
Buti, M.1
San Miguel, R.2
Brosa, M.3
-
9
-
-
85062055676
-
Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study
-
Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006;166:1632-1641.
-
(2006)
Arch Intern Med
, vol.166
, pp. 1632-1641
-
-
Weber, R.1
Sabin, C.A.2
Friis-Møller, N.3
-
10
-
-
34548057765
-
Hepatitis C in the HIV-infected patient
-
McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007;54:S47-S56.
-
(2007)
J Acquir Immune Defic Syndr
, vol.54
, pp. S47-S56
-
-
McGovern, B.H.1
-
11
-
-
84871487025
-
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
-
Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
-
(2012)
JAMA
, vol.308
, pp. 2584-2593
-
-
Van Der Meer, A.J.1
Veldt, B.J.2
Feld, J.J.3
-
12
-
-
0034619946
-
Peginterferon alfa-2a in patients with chronic hepatitis C
-
Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
-
(2000)
N Engl J Med
, vol.343
, pp. 1666-1672
-
-
Zeuzem, S.1
Feinman, S.V.2
Rasenack, J.3
-
13
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
14
-
-
1542378867
-
Peginterferon alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
-
(2004)
Ann Intern Med
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette, H.2
Morgan, T.R.3
-
15
-
-
80052058359
-
A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans
-
Butt AA, McGinnis K, Skanderson M, Justice AC. A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans. AIDS Res Hum Retroviruses 2011;27:973-979.
-
(2011)
AIDS Res Hum Retroviruses
, vol.27
, pp. 973-979
-
-
Butt, A.A.1
McGinnis, K.2
Skanderson, M.3
Justice, A.C.4
-
17
-
-
84911409020
-
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomized study
-
Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomized study. Lancet 2014; 384:1756-1765.
-
(2014)
Lancet
, vol.384
, pp. 1756-1765
-
-
Lawitz, E.1
Sulkowski, M.S.2
Ghalib, R.3
-
18
-
-
84900339263
-
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
-
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
-
(2014)
N Engl J Med
, vol.370
, pp. 1889-1898
-
-
Afdhal, N.1
Zeuzem, S.2
Kwo, P.3
-
19
-
-
84898669547
-
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
-
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
-
(2014)
N Engl J Med
, vol.370
, pp. 1483-1493
-
-
Afdhal, N.1
Reddy, K.R.2
Nelson, D.R.3
-
20
-
-
84900326091
-
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
-
Kowdley KV, Gordon SC, Reddy KR. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
-
(2014)
N Engl J Med
, vol.370
, pp. 1879-1888
-
-
Kowdley, K.V.1
Gordon, S.C.2
Reddy, K.R.3
-
21
-
-
84896696368
-
-
Titusville, NJ: Janssen Products
-
Olysio [package insert]. Titusville, NJ: Janssen Products, 2013.
-
(2013)
Olysio [package Insert]
-
-
-
24
-
-
84925614860
-
-
Foster City, CA: Gilead
-
Harvoni [package insert]. Foster City, CA: Gilead, 2014.
-
(2014)
Harvoni [package Insert]
-
-
-
25
-
-
84934319240
-
TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin
-
Abstract Presented at the
-
Wyles DL, Sulkowski MS, Eron JJ, et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. [Abstract 1939.] Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7-11, 2014a, Boston, MA.
-
65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7-11, 2014a, Boston, MA
-
-
Wyles, D.L.1
Sulkowski, M.S.2
Eron, J.J.3
-
26
-
-
84903795463
-
The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis
-
Yehia BR, Schranz AJ, Umschied CA, Lo Re V. The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis. PLoS One 2014;9:e101554.
-
(2014)
PLoS One
, vol.9
-
-
Yehia, B.R.1
Schranz, A.J.2
Umschied, C.A.3
Lo Re, V.4
-
27
-
-
84934319241
-
Cascade of hepatitis C care among HIV/HCV co-infected individuals at an urban HIV clinic in Pittsburgh, PA
-
Presented at the
-
th Annual Department of Medicine Research Day, May 22, 2014, Pittsburgh, PA.
-
th Annual Department of Medicine Research Day, May 22, 2014, Pittsburgh, PA
-
-
Pai, G.1
Mbata, I.2
Shut, K.3
Prasad, R.4
-
28
-
-
84904506394
-
The hepatitis C cascade of care among HIV infected patients: A call to address ongoing barriers to care
-
Cachay ER, Hill L, Wyles D, et al. The hepatitis C cascade of care among HIV infected patients: A call to address ongoing barriers to care. PLoS One. 2014;9:e102883.
-
(2014)
PLoS One
, vol.9
-
-
Cachay, E.R.1
Hill, L.2
Wyles, D.3
-
29
-
-
84883419062
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection
-
Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med 2013b;159:372.
-
(2013)
Ann Intern Med
, vol.159
, pp. 372
-
-
Chou, R.1
Wasson, N.2
-
30
-
-
75349088230
-
Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C
-
Castera L, Sebastiani G, Le BB, de L, V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010;52:191-198.
-
(2010)
J Hepatol
, vol.52
, pp. 191-198
-
-
Castera, L.1
Sebastiani, G.2
Le, B.B.3
De L, V.4
Couzigou, P.5
Alberti, A.6
-
31
-
-
84856575734
-
-
The University of Liverpool Available at: Last accessed August 29, 2014
-
HIV-Drug Interactions. The University of Liverpool. Available at: http://www.hiv-druginteractions.org (Last accessed August 29, 2014).
-
HIV-Drug Interactions
-
-
-
32
-
-
0036174438
-
Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors
-
Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-723.
-
(2002)
Antimicrob Agents Chemother
, vol.46
, pp. 716-723
-
-
Birkus, G.1
Hitchcock, M.J.2
Cihlar, T.3
-
33
-
-
84942053676
-
Ledipasvir/Sofosbuvir for 12 Weeks in Patients Coinfected With HCV and HIV-1
-
Abstract Presented at the
-
nd Conference for Retroviruses and Opportunistic Infections, February 23-26, 2015, Seattle, WA.
-
nd Conference for Retroviruses and Opportunistic Infections, February 23-26, 2015, Seattle, WA
-
-
Naggie, S.1
Cooper, C.2
Saag, M.3
-
34
-
-
84904991493
-
-
Available at: Last accessed March 12, 2015
-
EASL. Recommendations on Treatment of Hepatitis C 2014. Available at: http://easl.eu (Last accessed March 12, 2015).
-
(2014)
Recommendations on Treatment of Hepatitis C
-
-
-
35
-
-
84934319243
-
-
Uxbridge, UK: Bristol-Myers Squibb
-
Daklinza [package insert]. Uxbridge, UK: Bristol-Myers Squibb, 2015.
-
(2015)
Daklinza [package Insert]
-
-
-
36
-
-
84891825080
-
Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection
-
Karageorgopoulos D, El-Sherif O, Bhagani S, Khoo S. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis 2014;27:36-45.
-
(2014)
Curr Opin Infect Dis
, vol.27
, pp. 36-45
-
-
Karageorgopoulos, D.1
El-Sherif, O.2
Bhagani, S.3
Khoo, S.4
-
37
-
-
84939773045
-
Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection: ALLY-2 Study
-
Abstract Presented at the
-
nd Conference for Retroviruses and Opportunistic Infections, February 23-26, 2015, Seattle, WA.
-
nd Conference for Retroviruses and Opportunistic Infections, February 23-26, 2015, Seattle, WA
-
-
Wyles, D.1
Ruane, P.2
Sulkowski, M.3
-
39
-
-
84896460675
-
Hepatitis C virus NS5A inhibitors and drug resistance mutations
-
Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014;20:2902-2912.
-
(2014)
World J Gastroenterol
, vol.20
, pp. 2902-2912
-
-
Nakamoto, S.1
Kanda, T.2
Wu, S.3
Shirasawa, H.4
Yokosuka, O.5
-
40
-
-
84908665918
-
Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding
-
Issur M, Gotte M. Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding. Viruses 2014;6:4227-4241.
-
(2014)
Viruses
, vol.6
, pp. 4227-4241
-
-
Issur, M.1
Gotte, M.2
|